
About this session
In diagnostic allergy laboratories worldwide, two fully automated, rigorously quality-controlled immunoassay systems are used to quantify human IgE antibodies. Since our initial comparison in 2010, both systems have incorporated molecular allergens as reagents.
Proficiency program data over 14 years confirms excellent agreement in total IgE measurement between IMMULITE® and ImmunoCAP assays, attributed to a common calibrator.
However, caution is warranted when patients have received omalizumab therapy. While qualitative IgE antibody results align well with allergic disease presence, discrepancies arise in quantitative levels, particularly relevant when using non-confirmed specific IgE cutoffs to predict likelihood of food allergy.
Published predictive risk curves cannot be extrapolated between the two immunoassay systems or different patient populations. Notably, recent studies suggest closer agreement in allergen component-specific IgE results between the two systems, though further validation is required.